RT Journal Article
SR Electronic
T1 Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases
JF European Respiratory Review
JO EUROPEAN RESPIRATORY REVIEW
FD European Respiratory Society
SP 180078
DO 10.1183/16000617.0078-2018
VO 27
IS 150
A1 Holtze, Colin
A1 Flaherty, Kevin
A1 Kreuter, Michael
A1 Luppi, Fabrizio
A1 Moua, Teng
A1 Vancheri, Carlo
A1 Scholand, Mary B.
YR 2018
UL http://err.ersjournals.com/content/27/150/180078.abstract
AB There are over 200 interstitial lung diseases (ILDs). In addition to patients with idiopathic pulmonary fibrosis (IPF), a percentage of patients with other ILDs also develop progressive fibrosis of the lung during their disease course. Patients with progressive-fibrosing ILDs may show limited response to immunomodulatory therapy, worsening symptoms and lung function and, ultimately, early mortality. There are few data for ILDs that may present a progressive fibrosing phenotype specifically, but we believe the burden and healthcare costs associated with these conditions may be comparable to those reported in IPF. This review discusses the burden of ILDs that may present a progressive fibrosing phenotype and the factors impacting healthcare utilisation.Data for ILDs with a progressive fibrosing phenotype are lacking, but the burden and healthcare costs associated with these conditions may be comparable to those reported in IPF http://ow.ly/Eoht30mS4Nx